ECSP13012448A - Nuevas aminopirazoloquinazolinas. - Google Patents

Nuevas aminopirazoloquinazolinas.

Info

Publication number
ECSP13012448A
ECSP13012448A ECSP13012448A ECSP13012448A EC SP13012448 A ECSP13012448 A EC SP13012448A EC SP13012448 A ECSP13012448 A EC SP13012448A EC SP13012448 A ECSP13012448 A EC SP13012448A
Authority
EC
Ecuador
Prior art keywords
aminopirazoloquinazolinas
new
compounds
medicines
radicals
Prior art date
Application number
Other languages
English (en)
Inventor
Matthias Treu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037625&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP13012448A publication Critical patent/ECSP13012448A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

La presente invención comprende compuestos de la fórmula general (I)en donde los radicales R1 hasta R3 y X están definidos como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por una proliferación celular excesiva o anómala, a preparaciones farmacéuticas que contienen tales compuestos y a su empleo como medicamentos.
ECSP13012448 2010-07-23 2013-02-19 Nuevas aminopirazoloquinazolinas. ECSP13012448A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10170683 2010-07-23

Publications (1)

Publication Number Publication Date
ECSP13012448A true ECSP13012448A (es) 2013-03-28

Family

ID=43037625

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012448 ECSP13012448A (es) 2010-07-23 2013-02-19 Nuevas aminopirazoloquinazolinas.

Country Status (22)

Country Link
US (1) US8735386B2 (es)
EP (1) EP2595987B1 (es)
JP (1) JP5991974B2 (es)
KR (1) KR20130132394A (es)
CN (1) CN103097388A (es)
AP (1) AP2012006640A0 (es)
AR (1) AR082850A1 (es)
AU (1) AU2011281504A1 (es)
BR (1) BR112013000107A2 (es)
CA (1) CA2803467A1 (es)
CL (1) CL2012003745A1 (es)
CO (1) CO6670575A2 (es)
EA (1) EA201201661A1 (es)
EC (1) ECSP13012448A (es)
GE (1) GEP20156289B (es)
MA (1) MA34389B1 (es)
MX (1) MX2013000821A (es)
PE (1) PE20131143A1 (es)
SG (1) SG187548A1 (es)
TW (1) TW201217380A (es)
UY (1) UY33526A (es)
WO (1) WO2012010704A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150578B2 (en) * 2012-01-23 2015-10-06 Boehringer Ingelheim International Gmbh 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
KR20240006008A (ko) * 2013-11-15 2024-01-12 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온,이의 염 및 이의 용도
PL3250208T3 (pl) 2015-01-30 2021-04-06 Oncoceutics, Inc. 7-benzylo-4-(4-(trifluorometylo)benzylo)-1,2,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn-5(4h)-on oraz jego sole i ich zastosowanie w terapii
US10414769B2 (en) 2015-05-13 2019-09-17 Boehringer Ingelheim International Gmbh 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
CA3039012C (en) * 2016-11-11 2021-08-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
CN108484600B (zh) * 2017-05-26 2022-12-13 江苏新元素医药科技有限公司 促尿酸***的urat1抑制剂
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
EP3786161A4 (en) * 2018-04-24 2021-05-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd CDK4 / 6 INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC OF THEM AND ASSOCIATED USE
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3917514A4 (en) * 2019-01-30 2023-02-22 Yale University COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROSIS
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
CN113518775A (zh) * 2019-03-07 2021-10-19 生物技术公司 用于制备经取代的咪唑并喹啉的方法
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
CN113710225A (zh) * 2019-04-19 2021-11-26 范德生物公司 活性剂在皮肤内的递送和保留
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
AR120184A1 (es) 2019-10-11 2022-02-02 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
CA3181162A1 (en) 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
JP2024505714A (ja) * 2021-02-08 2024-02-07 メッドシャイン ディスカバリー インコーポレイテッド ５，６－ジドヒロチエノ［３，４－ｈ］キナゾリン系化合物
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ98998A3 (cs) * 1995-10-02 1998-10-14 F. Hoffmann-La Roche Ag Deriváty pyrimidinu jako antagonisty 5HT2C receptoru
ME00142B (me) 2003-05-22 2010-10-10 Nerviano Medical Sciences Srl Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法

Also Published As

Publication number Publication date
CL2012003745A1 (es) 2013-05-31
AU2011281504A1 (en) 2013-01-10
EA201201661A1 (ru) 2013-07-30
MA34389B1 (fr) 2013-07-03
EP2595987B1 (en) 2018-04-18
US20120238542A1 (en) 2012-09-20
JP5991974B2 (ja) 2016-09-14
TW201217380A (en) 2012-05-01
MX2013000821A (es) 2013-05-30
CN103097388A (zh) 2013-05-08
US8735386B2 (en) 2014-05-27
CO6670575A2 (es) 2013-05-15
EP2595987A1 (en) 2013-05-29
SG187548A1 (en) 2013-03-28
AP2012006640A0 (en) 2012-12-31
PE20131143A1 (es) 2013-10-23
JP2013532652A (ja) 2013-08-19
BR112013000107A2 (pt) 2016-05-17
CA2803467A1 (en) 2012-01-26
AR082850A1 (es) 2013-01-16
WO2012010704A1 (en) 2012-01-26
KR20130132394A (ko) 2013-12-04
GEP20156289B (en) 2015-05-25
UY33526A (es) 2012-02-29

Similar Documents

Publication Publication Date Title
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY33199A (es) 5-alquinil-pirimidinas.
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
ECSP11011558A (es) Nuevos compuestos químicos.
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
BR112012029647A2 (pt) novos derivados de pirimidinas
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
ECSP14013215A (es) Compuestos novedosos
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
CO6331434A2 (es) Nuevos compuestos
ECSP11011454A (es) 5-alquinil-piridinas
ECSP12012110A (es) 5-alquinil-pirimidinas
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
TN2013000012A1 (en) New aminopyrazoloquinazolines
ECSP12012115A (es) 5-alquinil-pirimidinas
UY33816A (es) ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?.